Avastin - (100 mg/4 mL; injection)

Generic Name	Bevacizumab	Innovator	Genentech, Inc.
Dosage	100 mg/4 mL; injection	Branded US Sales	More Than $1000 mn
Probable FTF	None	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	Less Than 5
Indication	Avastin, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****			*******	******** ** *****	** **** ******** ** **** **, ****
******			*******	******** ** *******	******** ** *** *, ****
******* *******			*******	****	****** **** ********

Chronology Of Events